Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNI-Free Interventions for Prevention of GVHD (BMT CTN 1301; Progress II)
NCT02345850Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Chronic GVHD-free, Relapse-free Survival Probability at 2 years. Started Aug 2015; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02345850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345850.